Cargando…

Extracorporeal adsorption of protective and toxic bile acids and bilirubin in patients with cholestatic liver dysfunction: a prospective study

BACKGROUND: The release of toxic bile acids (BAs) in the blood of critically ill patients with cholestatic liver dysfunction might lead to the damage of various organs. Their extracorporeal elimination using the cytokine adsorber Cytosorb(®) (CS) (adsorption of especially hydrophobic molecules < ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greimel, Antonia, Habler, Katharina, Gräfe, Caroline, Maciuga, Nils, Brozat, Clara Isabell, Vogeser, Michael, Zoller, Michael, Happich, Felix L., Liebchen, Uwe, Frank, Sandra, Paal, Michael, Scharf, Christina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635921/ https://www.ncbi.nlm.nih.gov/pubmed/37943350 http://dx.doi.org/10.1186/s13613-023-01198-7

Ejemplares similares

The effect of cytosorb® application on kidney recovery in critically ill patients with severe rhabdomyolysis: a propensity score matching analysis
por: Gräfe, Caroline, et al.
Publicado: (2023)

Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC–MS/MS method in human serum
por: Habler, Katharina, et al.
Publicado: (2021)

The cytokine adsorber Cytosorb® does not reduce ammonia concentrations in critically ill patients with liver failure
por: Liebchen, Uwe, et al.
Publicado: (2023)

Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study
por: Scharf, Christina, et al.
Publicado: (2021)

The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome
por: Scharf, Christina, et al.
Publicado: (2020)

Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness—Experience and Recommendations from One Year in Routine Clinical Practice
por: Scharf, Christina, et al.
Publicado: (2020)

Systematic Evaluation of Voriconazole Pharmacokinetic Models without Pharmacogenetic Information for Bayesian Forecasting in Critically Ill Patients
por: Kallee, Simon, et al.
Publicado: (2022)

The Role of Non-Enzymatic Degradation of Meropenem—Insights from the Bottle to the Body
por: Liebchen, Uwe, et al.
Publicado: (2021)

Estimation of inter-laboratory reference change values from external quality assessment data
por: Paal, Michael, et al.
Publicado: (2021)

Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis
por: Scharf, Christina, et al.
Publicado: (2021)

Can the cytokine adsorber CytoSorb(®) help to mitigate cytokine storm and reduce mortality in critically ill patients? A propensity score matching analysis
por: Scharf, Christina, et al.
Publicado: (2021)

Bile acids decrease intracellular bilirubin levels in the cholestatic liver: implications for bile acid-mediated oxidative stress
por: Muchova, Lucie, et al.
Publicado: (2011)

Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill Patients
por: Liebchen, Uwe, et al.
Publicado: (2021)

Was ist neu … in der Behandlung von invasiven Mykosen. COVID-19-assoziierte pulmonale Aspergillose
por: Scharf, Christina, et al.
Publicado: (2021)

Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study
por: Scharf, Christina, et al.
Publicado: (2022)

Evaluation of Newborn Direct Bilirubin As Screening for Cholestatic Liver Disease
por: Lerer, Rikah, et al.
Publicado: (2023)

An UHPLC-MS/MS method for quantification of the CDK4/6 inhibitor abemaciclib in human serum
por: Habler, Katharina, et al.
Publicado: (2022)

No clinically relevant removal of meropenem by cytokine adsorber CytoSorb(®) in critically ill patients with sepsis or septic shock
por: Liebchen, Uwe, et al.
Publicado: (2021)

Comparison of Cerebrospinal Fluid Collection Through the Proximal and Distal Port Below the Overflow System from an External Ventricular Drain
por: Kinast, Christina Barbara, et al.
Publicado: (2022)

Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease
por: Tyc, Olaf, et al.
Publicado: (2020)

CytoSorb® Hemoadsorption as a Promising Tool to Handle COVID-19-Induced Cytokine Storm
por: Acevedo, Alice-Christin, et al.
Publicado: (2021)

The role of bile acids in cholestatic liver injury
por: Cai, Shi-Ying, et al.
Publicado: (2021)

Pathobiochemical signatures of cholestatic liver disease in bile duct ligated mice
por: Abshagen, Kerstin, et al.
Publicado: (2015)

Detoxification of bilirubin and bile acids with intermittent coupled plasmafiltration and adsorption in liver failure (HERCOLE study)
por: Donati, Gabriele, et al.
Publicado: (2020)

Digestive enzymes of fungal origin as a relevant cause of false positive Aspergillus antigen testing in intensive care unit patients
por: Schroeder, Ines, et al.
Publicado: (2020)

Therapeutic drug monitoring-guided high dose meropenem therapy of a multidrug resistant Acinetobacter baumannii - A case report
por: Liebchen, U., et al.
Publicado: (2019)

Identification of a bilirubin receptor that may mediate a component of cholestatic itch
por: Meixiong, James, et al.
Publicado: (2019)

Bile Nephropathy in Flucloxacillin-Induced Cholestatic Liver Dysfunction
por: Alnasrallah, Basil, et al.
Publicado: (2016)

Bile acid-mediated signaling in cholestatic liver diseases
por: Zeng, Jing, et al.
Publicado: (2023)

Optimal loading dose of meropenem before continuous infusion in critically ill patients: a simulation study
por: Liebchen, Uwe, et al.
Publicado: (2021)

MRGPRX4 is a bile acid receptor for human cholestatic itch
por: Yu, Huasheng, et al.
Publicado: (2019)

Crosstalk between Gut Microbiota and Bile Acids in Cholestatic Liver Disease
por: Shi, Qingmiao, et al.
Publicado: (2023)

Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2(−/−) mice by modulating composition, signalling and excretion of faecal bile acids
por: Fuchs, Claudia Daniela, et al.
Publicado: (2018)

The protective effect of allopurinol on cholestatic liver injury induced by bile duct ligation.
por: Mun, K. C., et al.
Publicado: (1996)

Highlight report: Protection of cholestatic livers by shunting of bile from canaliculi to sinusoids
por: Abbass, Tahany, et al.
Publicado: (2018)

Studies on the mechanisms of bile acid initiated hepatic inflammation in cholestatic liver injury
por: Cai, Shi-Ying, et al.
Publicado: (2017)

Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis
por: Gui, Wenfang, et al.
Publicado: (2023)

Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2(−/−) mouse model of sclerosing cholangitis via immunomodulatory effects
por: Fuchs, Claudia D., et al.
Publicado: (2022)

Hormesis in Cholestatic Liver Disease; Preconditioning with Low Bile Acid Concentrations Protects against Bile Acid-Induced Toxicity
por: Verhaag, Esther M., et al.
Publicado: (2016)

Noninvasive monitoring of bilirubin photoisomer excretion during phototherapy
por: Uchida, Yumiko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ljgmt84mblvd0odehk2s501vqv